Cost Effectiveness of Rivaroxaban for Stroke Prevention in German Patients with Atrial Fibrillation.
- Published in:
- PharmacoEconomics, 2015, v. 33, n. 3, p. 271, doi. 10.1007/s40273-014-0236-9
- By:
- Publication type:
- Article
Works matching IS 11707690 AND DT 2015 AND VI 33 AND IP 3
Results: 8
1
2
A Systematic Review of Cost-Effectiveness Analyses of Drugs for Postmenopausal Osteoporosis.
- Published in:
- PharmacoEconomics, 2015, v. 33, n. 3, p. 205, doi. 10.1007/s40273-014-0231-1
- By:
- Publication type:
- Article
3
Alteplase for the Treatment of Acute Ischaemic Stroke: A NICE Single Technology Appraisal; an Evidence Review Group Perspective.
- Published in:
- PharmacoEconomics, 2015, v. 33, n. 3, p. 225, doi. 10.1007/s40273-014-0233-z
- By:
- Publication type:
- Article
4
Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework.
- Published in:
- PharmacoEconomics, 2015, v. 33, n. 3, p. 255, doi. 10.1007/s40273-014-0235-x
- By:
- Publication type:
- Article
5
Costs of Health Resource Utilization Among HIV-Positive Individuals in British Columbia, Canada: Results From a Population-Level Study.
- Published in:
- PharmacoEconomics, 2015, v. 33, n. 3, p. 243, doi. 10.1007/s40273-014-0229-8
- By:
- Publication type:
- Article
6
Is There an Economic Rationale for Cancer Drugs to Have a Separate Reimbursement Review Process for Resource Allocation Purposes?
- Published in:
- PharmacoEconomics, 2015, v. 33, n. 3, p. 235, doi. 10.1007/s40273-014-0238-7
- By:
- Publication type:
- Article
7
Is it Time to Update Societal Value Sets for Preference-Based Measures of Health?
- Published in:
- PharmacoEconomics, 2015, v. 33, n. 3, p. 191, doi. 10.1007/s40273-015-0253-3
- By:
- Publication type:
- Article
8
Resource Modelling: The Missing Piece of the HTA Jigsaw?
- Published in:
- PharmacoEconomics, 2015, v. 33, n. 3, p. 193, doi. 10.1007/s40273-014-0228-9
- By:
- Publication type:
- Article